Spoken Alpha
Onconetix, Inc.
Onconetix, Inc. provides diagnostic tests for prostate cancer and men's health products. The company's lead product, Proclarix, is a blood-based diagnostic test approved for sale in Europe that helps identify clinically significant prostate cancer in patients with elevated PSA levels, reducing unnecessary biopsies.
Onconetix, Inc is a Healthcare company operating in Biotechnology with a $2.9M market cap.
Most recent reported earnings: Q2 FY2026 (Aug 12, 2026).
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
We index calls for roughly 3,000 US-listed companies. If you'd like us to add ONCO, reply to your welcome email and we'll prioritize it.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for ONCO.
$ curl https://api.spokenalpha.com/v1/companies/ONCOFAQ
Spoken Alpha indexes ONCO's earnings call transcripts at https://spokenalpha.com/companies/ONCO. Each call links to attributed speakers and parsed analyst Q&A. Onconetix, Inc.'s own investor relations page is at https://ir.onconetix.com/.
Onconetix, Inc. (ONCO) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-12 | $-1.28 | — | — | $17.1K | — | — | EODHD |
| Q1 FY2026 | 2026-05-10 | $0.00 | $0.00 | — | $21.5K | — | — | EODHD |
| Q4 FY2025 | 2026-03-11 | $0.00 | $0.00 | — | $303.6K | — | — | EODHD |
| Q3 FY2025 | 2025-11-27 | $-6.25 | $0.00 | — | $303.7K | — | — | EODHD |
| Q2 FY2025 | 2025-08-28 | $-4.18 | $0.00 | — | $106.5K | — | — | EODHD |
| Q1 FY2025 | 2025-05-29 | $-45.44 | — | — | $101.6K | — | — | EODHD |
| Q4 FY2024 | 2025-03-05 | $-2.93 | — | — | $712.0K | — | — | EODHD |
| Q3 FY2024 | 2024-11-06 | $-249.08 | — | — | $406.9K | — | — | EODHD |
| Q2 FY2024 | 2024-08-11 | $-2191.49 | — | — | $704.8K | — | — | EODHD |
| Q1 FY2024 | 2024-05-19 | $-0.50 | $-0.21 | -100.0% | $700.4K | — | — | EODHD |
| Q4 FY2023 | 2024-03-06 | $-3404.00 | $-0.21 | -100.0% | $58.5K | — | — | EODHD |
| Q3 FY2023 | 2023-11-16 | $-52700.03 | $-32300.02 | -63.2% | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-08-13 | $-612.00 | $-0.18 | -100.0% | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-05-11 | $-30600.02 | $-34850.02 | +12.2% | $0 | — | — | EODHD |
| Q4 FY2022 | 2023-03-08 | $-680.00 | $-0.20 | -100.0% | $0 | — | — | EODHD |
| Q3 FY2022 | 2022-11-09 | $-918.00 | $-0.27 | -100.0% | — | — | — | EODHD |
| Q2 FY2022 | 2022-08-14 | $-0.36 | — | — | — | — | — | EODHD |
| Q1 FY2022 | 2022-05-12 | $-0.34 | — | — | — | — | — | EODHD |
| Q4 FY2021 | 2022-02-22 | $-0.12 | $0.00 | — | — | — | — | EODHD |
| Q3 FY2021 | 2021-11-04 | $-0.05 | $0.00 | — | — | — | — | EODHD |
Source: EODHD. ONCO reported actuals as published; sparse fields render as —.